Should minimal residual disease (MRD) testing be routinely performed?

In this week’s video, Dr. Durie discusses if minimal residual disease (MRD) testing should be routinely performed, and the potential use for MRD testing in the near future.

The BOTTOM LINE:
MRD testing will hopefully be a surrogate marker in clinical trials soon. However, at this time, routine MRD testing is not currently recommended.

Please subscribe to our channel!
Subscribe to International Myeloma Foundation:

Visit our website at:

Find us online:
Facebook:
Google+:
IMF on twitter: @IMFMyeloma (
Dr. Durie on twitter: @BrianDurieMD (

Support the IMF!
Category
Nonprofits & Activism
License
Standard YouTube License

myeloma,multiple myeloma,cancer,bone marrow cancer,cancer treatment,cancer research,bone disease,dr brian durie,susie novis,bone marrow,multiple myeloma cancer,bone cancer,bone marrow disease,blood cancer,blood plasma cancer,yt:cc=on,